Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Hepatology

• Publication date

  2008-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hep.22543PMID 18925643
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of Asian Race on Response to Combination Therapy With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C

  2007cited by this paper
• Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.

  2007cited by this paper
• Th1 response during ribavirin and interferon-α combination therapy in chronic hepatitis C

  2006cited by this paper
• Peginterferon alfa‐2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response

  2006cited by this paper
• Th1 response during ribavirin and interferon-alpha combination therapy in chronic hepatitis C.

  2006cited by this paper
• Predictive factors of virological non‐response to interferon–ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load

  2006cited by this paper
• IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection

  2006cited by this paper
• Metabolic factors involved in the therapeutic response of patients with hepatitis C virus‐related chronic hepatitis

  2006cited by this paper
• Maintenance of T1 response as induced during PEG-IFNalpha plus ribavirin therapy controls viral replication in genotype-1 patients with chronic hepatitis C.

  2005cited by this paper
• Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

  2005cited by this paper
• Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon‐alpha 2a and ribavirin according to virological response

  2005cited by this paper
• Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences

  2004cited by this paper
• Lymphocyte T helper‐specific reactivity in sustained responders to interferon and ribavirin with negativation (seroreversion) of anti‐hepatitis C virus

  2004cited by this paper
• Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection.

  2003cited by this paper
• Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C

  2003cited by this paper
• High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C

  2003cited by this paper
• Long-term changes of peripheral blood CD4-positive T cell subsets (Th1, Th2) in chronic hepatitis C patients with a sustained response or no response to IFN.

  2003cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Lower Th-1/Th-2 Ratio Before Interferon Therapy May Favor Long-Term Virological Responses in Patients with Chronic Hepatitis C

  2002cited by this paper
• Immunological markers predicting outcome in patients with hepatitis C treated with interferon‐α and ribavirin

  2002cited by this paper
• High body mass index is an independent risk factor for non-response to antiviral treatment in chronic hepatitis C

  2001cited by this paper
• Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: A retrospective cohort study of 738 patients

  2000cited by this paper
• Increased frequency of interferon-γ-producing peripheral blood CD4+ T cells in chronic hepatitis C virus infection

  2000cited by this paper
• Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group.

  1999cited by this paper
• Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long‐term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis

  1999cited by this paper
• Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan

  1999cited by this paper
• Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response.

  1999cited by this paper
• Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

  1999cited by this paper
• Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.

  1998cited by this paper
• Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C

  1998cited by this paper
• New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a

  1997cited by this paper
• Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein.

  1997cited by this paper
• Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

  1996cited by this paper
• Viral and host factors that contribute to efficacy of interferon-α[2a] therapy in patients with chronic hepatitis C

  1995cited by this paper
• Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C.

  1994cited by this paper
• Viral and host factors that contribute to efficacy of interferon-α2a therapy in patients with chronic hepatitis C

  1994cited by this paper
• Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.

  1990cited by this paper
• Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus

  1990cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Highly replicating hepatitis C virus variants emerge in immunosuppressed patients causing severe disease

  2025cites this paper
• Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C

  2018cites this paper
• Genetic variants in chemokine CC subfamily genes influence hepatitis C virus viral clearance

  2018cites this paper
• Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9

  2017cites this paper
• Sequence Heterogeneity in the Core and NS5A Region of Hepatitis C Virus (HCV) and IL-28B Polymorphisms in Predicting Treatment Response among Chronic HCV Genotype 4 Infected Egyptian Patients

  2017cites this paper
• Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus

  2017cites this paper
• Amino Acid Substitution in Hepatitis C Virus Core and Genetic Variation in Interleukin 28β Gene and their Correlation to Interferon Treatment Failure in Chronic HCV Egyptian Patients

  2017cites this paper
• Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C

  2017cites this paper
• Viral and host factors associated with outcomes of hepatitis C virus infection (Review).

  2017cites this paper
• Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment

  2017cites this paper
• Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3?

  2016influential citation
• Treatment Response of Chronic Hepatitis C Patients and Health-Related Quality of Life

  2016cites this paper
• Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy: A meta-analysis.

  2016cites this paper
• Efetividade de interferon peguilado e ribavirina no tratamento da hepatite C crônica em pacientes atendidos em um centro universitário no Estado de São Paulo

  2016cites this paper
• Influence of IL10 Gene polymorphisms on the sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy.

  2016cites this paper
• Viral Variation and Response to Therapy

  2016cites this paper
• Serum Adiponectin, Vitamin D, and Alpha-Fetoprotein in Children with Chronic Hepatitis C: Can They Predict Treatment Response?

  2015cites this paper
• Significance of miRNA‐122 in chronic hepatitis C patients with serotype 1 on interferon therapy

  2015cites this paper
• Czy parametry laboratoryjne mogą być czynnikami predykcyjnymi skuteczności leczenia chorych z przewlekłym wirusowym zapaleniem wątroby typu C

  2015cites this paper
• Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study

  2015cites this paper
• Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy

  2015cites this paper
• A Novel Approach to Identify Candidate Prognostic Factors for Hepatitis C Treatment Response Integrating Clinical and Viral Genetic Data

  2015cites this paper
• Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness

  2015cites this paper
• The role of IL‐28, IFN‐γ, and TNF‐α in predicting response to pegylated interferon/ribavirin in chronic HCV patients

  2015cites this paper
• Relationship between IL28B gene rs8099917 polymorphism and SVR in Turkish patients with hepatitis C virus genotype 1.

  2015cites this paper
• Prediction of Week 4 Virological Response in Hepatitis C for Making Decision on Triple Therapy: The Optim Study

  2015cites this paper
• Histopathological predictors of virological response in chronic hepatitis C patients

  2015cites this paper
• The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C

  2015cites this paper
• Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.

  2014cites this paper
• Vitamin D deficiency in chronic liver disease.

  2014cites this paper
• Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.

  2014cites this paper
• Neutrophil-to-Lymphocyte Ratio as a Predictor of Response to Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C

  2014cites this paper
• Predicting the Outcomes of Combination Therapy in Patients With Chronic Hepatitis C Using Artificial Neural Network

  2014cites this paper
• Progress in Virological Response in the Difficult-to-Treat Patients with Genotype 1 Hepatitis C Virus ( HCV ) Infection and Factors Correlated

  2014cites this paper
• Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients

  2014cites this paper
• The impact of clinicopathological parameters in predicting response to pegylated interferon and ribavirin in chronic hepatitis C patients

  2014cites this paper
• Quantitation of substitutions at amino acid 70 in hepatitis C virus genotype 1b

  2014cites this paper
• Impact of IL28B polymorphism on treatment induced viral clearance in HCV infected Egyptian patients

  2014cites this paper
• Establishment of a Practical Workflow Using a Next Generation Sequencer to Search for Novel SNPs Associated with the Anti-HCV Treatment Response

  2014cites this paper
• The role of vitamin D in chronic viral hepatitis

  2014cites this paper
• Indices of initial hepatitis C virus RNA reduction rate to predict efficacy of interferon‐beta followed by peginterferon plus ribavirin for genotype 1b high viral load

  2014cites this paper
• Association between low molecular polypeptide 7 single nucleotide polymorphism and response to therapy in hepatitis C virus infection.

  2013cites this paper
• The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C.

  2013cites this paper
• Guidelines for the Management of Hepatitis C Virus Infection

  2013cites this paper
• Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

  2013cites this paper
• The effectiveness of traditional Japanese medicine (Kampo), in combination with pegylated interferon α plus ribavirin for patients with chronic hepatitis C: A pilot study

  2013cites this paper
• Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4

  2013cites this paper
• Antiviral treatment of hepatitis C virus infection and factors affecting efficacy.

  2013cites this paper
• Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study

  2013cites this paper
• Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4

  2013cites this paper
• Impact of IL-28 B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4

  2013cites this paper
• Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?

  2013cites this paper
• Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy.

  2013cites this paper
• Preparing the patient for success: treat or wait?

  2013cites this paper
• Rapid virological response as a predictor of a sustained virological response in Egyptian patients with chronic hepatitis C genotype 4

  2013cites this paper
• Dual role of IL-12 in the therapeutic efficacy or failure during combined PEG-Interferon-α2A and ribavirin therapy in patients with chronic hepatitis C.

  2013cites this paper
• The long way toward understanding host and viral determinants of therapeutic success in HCV infection

  2012cites this paper
• Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score

  2012cites this paper
• Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients.

  2012cites this paper
• Changes in sequences of core region, interferon sensitivity‐determining region and interferon and ribavirin resistance‐determining region of hepatitis C virus genotype 1 during interferon‐alpha and ribavirin therapy, and efficacy of retreatment

  2012cites this paper
• Liver Follicular Helper T-Cells Predict the Achievement of Virological Response following Interferon-Based Treatment in HCV-Infected Patients

  2012cites this paper
• Inter‐genotypic recombinant hepatitis C virus strains in Japan noted by discrepancies between immunoassay and sequencing

  2012cites this paper
• Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.

  2012cites this paper
• Discovery of critical host factor, IL‐28B, associated with response to hepatitis C virus treatment

  2012cites this paper
• D-livering the message: the importance of vitamin D status in chronic liver disease.

  2012influential citation
• A Lower Serum Gamma-Glutamyltransferase Level Does Not Predict a Sustained Virological Response in Patients with Chronic Hepatitis C Genotype 1

  2012influential citation
• HCV Positive Peripheral Blood Mononuclear Cells : Role in Treatment Personalization

  2012cites this paper
• Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype

  2012cites this paper
• Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic

  2012cites this paper
• Effects of mutation number in interferon sensitivity determining region on peripheral blood CD4+ T cell subsets (Th1, Th2) in chronic hepatitis C patients with hepatitis C virus genotype 1b and high viral load

  2012cites this paper
• Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.

  2012cites this paper
• Test of IL28B Polymorphisms in Chronic Hepatitis C Patients Treated with PegIFN and Ribavirin Depends on HCV Genotypes: Results from a Meta-Analysis

  2012cites this paper
• Analysis of the Virus Dynamics Model Reveals That Early Treatment of HCV Infection May Lead to the Sustained Virological Response

  2012cites this paper
• Comparison of three different methods for the evaluation of IL28 and ITPA polymorphisms in patients infected with HCV.

  2012cites this paper
• Treatment Guidelines of Hepatitis C

  2012cites this paper
• Impact of Pegylated Interferon Therapy on Outcomes of Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Hepatic Resection

  2012influential citation
• Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients.

  2012cites this paper
• Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment.

  2012cites this paper
• Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients.

  2011cites this paper
• Failure to achieve 2-log10 viral decrease in first four weeks of peg-IFNalpha-2b plus ribavirin therapy for chronic hepatitis C with genotype 1b and high viral titer is useful in predicting non-response: evaluation of response-guided therapy.

  2011cites this paper
• Modulation of CD4+ T cell responses following splenectomy in hepatitis C virus‐related liver cirrhosis

  2011cites this paper
• Mechanisms of non-response to antiviral treatment in chronic hepatitis C.

  2011cites this paper
• Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection.

  2011cites this paper
• Prediction of Effect of Pegylated Interferon Alpha-2b plus Ribavirin Combination Therapy in Patients with Chronic Hepatitis C Infection

  2011cites this paper
• Novel findings for the development of drug therapy for various liver diseases: Genetic variation in IL-28B is associated with response to the therapy for chronic hepatitis C.

  2011cites this paper
• Amino Acid Substitution in HCV Core/NS5A Region and Genetic Variation Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy

  2011cites this paper
• Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study

  2011cites this paper
• Prediction of response to peginterferon‐alfa‐2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b

  2011influential citation
• Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.

  2011cites this paper
• Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated‐interferon/ribavirin combination therapy

  2011cites this paper
• Simple formula to predict response to peginterferon alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads

  2011cites this paper
• Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated‐interferon‐alpha 2b and ribavirin combination therapy

  2011cites this paper
• Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C

  2011cites this paper
• Association of Interleukin-28B and Hepatitis C Genotype 1 with a High Viral Load and Response to Pegylated Interferon plus Ribavirin Therapy

  2011cites this paper
• Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection

  2011cites this paper
• Cholesterol and chronic hepatitis C virus infection

  2011cites this paper
• The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection

  2011cites this paper
• Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin

  2011cites this paper
• Lymphocytosis as a predictor of poor response to treatment of hepatitis C.

  2011cites this paper
• Sequences in the interferon sensitivity‐determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG‐interferon plus ribavirin: Data mining analysis

  2011cites this paper